FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT C	F CHANGES IN	BENEFICIAL	OWNERSHIP
• ., = •			• • • • • • • • • • • • • • • • • • • •

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	ourden								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Buell Jennifer				2. Issuer Name and Ticker or Trading Symbol MiNK Therapeutics, Inc. [INKT]									ck all applica Director Officer (tionship of Reporting P all applicable) Director Officer (give title below) Chief Execut		10% Ov	vner		
(Last) (First) (Middle) 149 FIFTH AVENUE, SUITE 500					3. Date of Earliest Transaction (Month/Day/Year) 01/09/2023											below)	Officer		
(Street) NEW YORK NY 10010			4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line)	X Form filed by One Reporting Person Form filed by More than One Reporting							
(City)	(8	state)	(Zip)												Person				
		Та	ble I - Nor	n-Deriv	ativ	/e Se	ecurities	s Acc	quired,	Dis	posed c	of, or B	enef	ficially	Owned				
1. Title of Security (Instr. 3) 2. Trans: Date (Month/I					Execution Date,		, Transaction Disposed O Code (Instr.		ties Acquired (A) or I Of (D) (Instr. 3, 4 and		() or , 4 and 5)	5. Amoun Securities Beneficia Owned Fo Reported	Form y (D) or		: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	v	Amount	int (A) or (D)		Price	Transaction(s) (Instr. 3 and 4)				(5 4)	
Common Stock ⁽¹⁾ 01/				01/09	9/2023				A		171,990 A \$2		\$2.32(2	(2) 380,715			D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Yo	Co	ansac		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisal Expiration Date (Month/Day/Year		of Securities		curity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ct (Instr. 4)	
				Co	ode	v	(A)	(A) (D) E			Expiration Date	or Num		nount mber Shares		(Instr. 4)			
Stock Option	\$2.32	01/09/2023		1	A		500,000		(3)	0	01/09/2033	Commor Stock	50	00,000	\$0.00	500,00	00	D	

Explanation of Responses:

- 1. Reflects the executive's 2022 performance bonus award paid in MiNK Therapeutics, Inc. common stock. The stock issued is fully-vested on the date of issuance but is subject to a lockup restriction with 50% of the award released on March 24, 2023 and 50% of the award released on June 24, 2023.
- 2. \$2.32 was the fair market value of MiNK Therapeutics, Inc. Common Stock on January 9, 2023, the stock issuance date.
- 3. Option was granted on January 9, 2023 and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. Option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the grant date, with the remainder vesting in equal quarterly installments thereafter.

Remarks:

By: /s/ Christine Klaskin, Attorney-in-Fact for Jennifer S. 01/11/2023 **Buell**

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.